Security key
68403P203
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP)
CUSIP: 68403P203
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock par value $0.012 per share
- Total 13F shares
- 13,240,569
- Total 13F value
- $45,015,425
- Share change
- +2,083,348
- SEC-reported price per share
- $3.40
- Number of holders
- 63
- Value change
- +$7,189,137
- Number of buys
- 34
- Number of sells
- 24
- Shares outstanding
- 41,050,760
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
63
Top holders
10
ORMP full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
ORAMED PHARMACEUTICALS INC. SEC filings
ORAMED PHARMACEUTICALS INC. company facts
ORAMED PHARMACEUTICALS INC. 13D/G history
Broader feeds
Reporting periods
Holder history for CUSIP 68403P203
Recent filing periods:
Ownership snapshot
Top reported holders of ORMP - ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nadav Kidron
Disclosed value leader
Nadav Kidron
Comparable rows
15/15
Latest evidence
30 Mar 2026
3/4/5
13D/G
13F
Lead comparable stake: 7.6%
13D/G row: Nadav Kidron
Showing 1-6 of 15 holder rows.
Quick read
Nadav Kidron leads the comparable SEC ownership view at 7.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nadav Kidron's linked filing trail.
Comparable ownership
Top 5
Nadav Kidron
7.6%
Aquamarine Financial (Cayman) Ltd
5.1%
Benjamin Shapiro
4.9%
Miriam Kidron
2.8%
Arie Mayer
0.41%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nadav Kidron |
3/4/5
13D/G
President and CEO, Director
|
7.6%
from 13D/G
|
$10,112,492
3,548,243 shares
|
— | 30 Mar 2026 |
| Aquamarine Financial (Cayman) Ltd |
13D/G
13F
Company
|
5.1%
|
$7,760,601
2,047,652 shares
|
$0 | 14 Jan 2026 |
| Benjamin Shapiro |
3/4/5
Director
|
4.9%
|
$6,150,588
2,023,220 shares
|
— | 31 Dec 2025 |
| Miriam Kidron |
3/4/5
Chief Scientific Officer, Director
|
2.8%
|
$3,229,443
1,133,138 shares
|
— | 30 Mar 2026 |
| Arie Mayer |
3/4/5
Director
|
0.41%
|
$510,747
168,009 shares
|
— | 31 Dec 2025 |
| Leonard Sank |
3/4/5
Director
|
0.33%
|
$301,349
134,531 shares
|
— | 05 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
63
Shares
13,240,569
Rows available
63
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
57
Q1 2026 holders
63
Holder diff
6
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend